Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants of concern (VOCs) in real time is key to inform public health policies. Serum neutralizing antibody titers are the current best correlate of protection from SARS-CoV-2 challenge in non-human primates and a key metric to understand immune evasion of VOCs. We report that vaccinated BALB/c mice do not recapitulate faithfully the breadth and potency of neutralizing antibody responses elicited by various vaccine platforms against VOCs, compared with non-human primates or humans, suggesting caution should be exercised when interpreting data obtained with this animal model.
Trial registration: ClinicalTrials.gov NCT05007951 .
Keywords: COVID-19; CP: Immunology; CP: Microbiology; SARS-CoV-2; antibodies; humans; mouse; non-human primates; vaccines.
【저자키워드】 COVID-19, antibodies, SARS-CoV-2, Vaccines., non-human primates, humans, mouse, CP: Immunology, CP: Microbiology, 【초록키워드】 public health, coronavirus, Vaccines, Antibody Response, SARS-CoV-2 variant, animal model, immune evasion, VOCs, understanding, vaccine platform, non-human primate, Neutralizing antibody response, Neutralizing antibody titer, breadth, real time, acute respiratory syndrome, BALB/c mice, approved, elicited, 【제목키워드】 Human, SARS-CoV-2 variant, sensitivity, mice,